Log in

SQZ Biotechnologies Stock Forecast, Price & News

-1.49 (-5.41 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $26.05
50-Day Range N/A
52-Week Range
Now: $26.05
Volume55,700 shs
Average Volume195,333 shs
Market Capitalization$624.47 million
P/E RatioN/A
Dividend YieldN/A
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company's lead product candidate, SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone617 758 8672



Sales & Book Value

Annual SalesN/A



Market Cap$624.47 million
Next Earnings DateN/A
OptionableNot Optionable
-1.49 (-5.41 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SQZ News and Ratings via Email

Sign-up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

SQZ Biotechnologies (NYSE:SQZ) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of SQZ Biotechnologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SQZ Biotechnologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SQZ Biotechnologies
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than SQZ Biotechnologies?

Wall Street analysts have given SQZ Biotechnologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but SQZ Biotechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for SQZ?

3 analysts have issued 12 month target prices for SQZ Biotechnologies' stock. Their forecasts range from $37.00 to $40.00. On average, they expect SQZ Biotechnologies' share price to reach $38.33 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price.
View analysts' price targets for SQZ Biotechnologies

Who are some of SQZ Biotechnologies' key competitors?

Who are SQZ Biotechnologies' key executives?

SQZ Biotechnologies' management team includes the following people:
  • Dr. Armon R. Sharei, Co-Founder, Pres, CEO & Director (Age 33, Pay $634.27k)
  • Ms. Teri Loxam, Chief Financial Officer (Age 48, Pay $430.52k)
  • Dr. Oliver Rosen, Chief Medical Officer (Age 56, Pay $688.36k)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 71)
  • Dr. Howard Bernstein, Chief Scientific Officer (Age 63)
  • Mr. Lawrence J. Knopf, Gen. Counsel & Sec. (Age 58)
  • Mr. David First, Chief People Officer (Age 56)
  • Mr. Micah Zajic, Chief Bus. Officer (Age 39)
  • Ms. Alex Balcom, VP of Fin. & Treasurer

When did SQZ Biotechnologies IPO?

(SQZ) raised $75 million in an IPO on Friday, October 30th 2020. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Securities and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

What is SQZ Biotechnologies' stock symbol?

SQZ Biotechnologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "SQZ."

When does SQZ Biotechnologies' quiet period expire?

SQZ Biotechnologies' quiet period expires on Wednesday, December 9th. SQZ Biotechnologies had issued 4,411,765 shares in its initial public offering on October 30th. The total size of the offering was $70,588,240 based on an initial share price of $16.00. During SQZ Biotechnologies' quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SQZ Biotechnologies' stock price today?

One share of SQZ stock can currently be purchased for approximately $26.05.

How big of a company is SQZ Biotechnologies?

SQZ Biotechnologies has a market capitalization of $624.47 million. SQZ Biotechnologies employs 101 workers across the globe.

What is SQZ Biotechnologies' official website?

The official website for SQZ Biotechnologies is www.sqzbiotech.com.

How can I contact SQZ Biotechnologies?

The company can be reached via phone at 617 758 8672.

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.